![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: OLFML2B |
Gene summary for OLFML2B |
![]() |
Gene information | Species | Human | Gene symbol | OLFML2B | Gene ID | 25903 |
Gene name | olfactomedin like 2B | |
Gene Alias | OLFML2B | |
Cytomap | 1q23.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | B4DWE8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25903 | OLFML2B | EOLP-1 | Human | Oral cavity | EOLP | 2.52e-03 | 1.42e-01 | -0.0202 |
25903 | OLFML2B | EOLP-2 | Human | Oral cavity | EOLP | 1.53e-02 | 1.54e-01 | -0.0203 |
25903 | OLFML2B | ATC12 | Human | Thyroid | ATC | 1.06e-50 | 1.03e+00 | 0.34 |
25903 | OLFML2B | ATC13 | Human | Thyroid | ATC | 1.96e-97 | 2.19e+00 | 0.34 |
25903 | OLFML2B | ATC2 | Human | Thyroid | ATC | 7.44e-07 | 5.04e-01 | 0.34 |
25903 | OLFML2B | ATC4 | Human | Thyroid | ATC | 1.35e-60 | 1.25e+00 | 0.34 |
25903 | OLFML2B | ATC5 | Human | Thyroid | ATC | 2.62e-100 | 2.29e+00 | 0.34 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003019811 | Oral cavity | EOLP | extracellular matrix organization | 52/2218 | 301/18723 | 3.29e-03 | 1.90e-02 | 52 |
GO:004306211 | Oral cavity | EOLP | extracellular structure organization | 52/2218 | 302/18723 | 3.52e-03 | 2.01e-02 | 52 |
GO:004522911 | Oral cavity | EOLP | external encapsulating structure organization | 52/2218 | 304/18723 | 4.04e-03 | 2.23e-02 | 52 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OLFML2B | SNV | Missense_Mutation | novel | c.365C>A | p.Pro122Gln | p.P122Q | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
OLFML2B | SNV | Missense_Mutation | rs374641911 | c.1537N>T | p.Arg513Trp | p.R513W | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
OLFML2B | SNV | Missense_Mutation | novel | c.2104G>A | p.Asp702Asn | p.D702N | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
OLFML2B | SNV | Missense_Mutation | novel | c.1739G>A | p.Arg580His | p.R580H | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
OLFML2B | SNV | Missense_Mutation | novel | c.1357G>A | p.Val453Met | p.V453M | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
OLFML2B | SNV | Missense_Mutation | c.1121N>T | p.Ser374Leu | p.S374L | protein_coding | tolerated(0.34) | benign(0) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | ||
OLFML2B | SNV | Missense_Mutation | c.2206N>C | p.Ala736Pro | p.A736P | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
OLFML2B | SNV | Missense_Mutation | rs776955703 | c.127N>A | p.Glu43Lys | p.E43K | protein_coding | deleterious(0.04) | benign(0.181) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
OLFML2B | SNV | Missense_Mutation | c.373N>T | p.Leu125Phe | p.L125F | protein_coding | deleterious(0) | possibly_damaging(0.621) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | ||
OLFML2B | SNV | Missense_Mutation | novel | c.1597A>G | p.Asn533Asp | p.N533D | protein_coding | deleterious(0.04) | possibly_damaging(0.609) | TCGA-OL-A5RX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |